Fulcrum Therapeutics shares are trading lower after the company announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
Portfolio Pulse from Benzinga Newsdesk
Fulcrum Therapeutics' shares fell after the company's Phase 3 REACH trial for losmapimod in FSHD patients failed to meet its primary endpoint.
September 12, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fulcrum Therapeutics' Phase 3 REACH trial for losmapimod in FSHD patients did not meet its primary endpoint, leading to a decline in share price.
The failure to meet the primary endpoint in a Phase 3 trial is a significant setback for any biotech company, as it can delay or prevent the drug from reaching the market. This news likely led to a decrease in investor confidence, resulting in a drop in Fulcrum Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100